[caption id="attachment_69662" align="alignleft" width="150"] Maria Gikoska[/caption] MedicalResearch.com Interview with: Maria Gikoska, MBS Geisinger College of Health Sciences Scranton, PA 18509 MedicalResearch.com: What is the background for this study? Response: Opioid use disorder (OUD) is a chronic condition that continues to substantially impact public health in the United States (U.S.), with approximately 5.7 million people affected in 2023. Buprenorphine, a partial mu-opioid receptor agonist, is widely used for treating OUD due to its safety profile, high treatment retention, and effectiveness in reducing opioid-related mortality. Since its approval in 2002, its use has increased, though not uniformly across states. Factors such as the now- eliminated X-waiver, telemedicine expansions during the COVID-19 pandemic, and differing state level policies have influenced buprenorphine access. The study sought to evaluate national and state-level pattern in buprenorphine distribution from 2019-2023 to understand disparities and inform public health interventions.